)
David de Vries
Co-Founder and CEO
Tr1X
David de Vries is co-founder and CEO of Tr1X, a clinical-stage biotechnology company developing off-the-shelf Type 1 regulatory T (Tr1) and CAR Tr1 cell therapies designed to restore immune tolerance and treat autoimmune and inflammatory diseases. Tr1X is advancing two first-in-class programs: TRX103, the first allogeneic engineered Tr1 therapy currently in Phase 1/2a trials for graft-versus-host disease prevention and treatment-refractory Crohn’s disease, and TRX319, an allogeneic CD19 CAR Tr1 therapy currently enrolling in a Phase 1/2a trial for progressive multiple sclerosis. Under his leadership, the company has raised more than $130 million in equity financing and nondilutive grants. Previously, de Vries co-founded Arine, an AI-driven medication optimization platform serving health plans, PBMs, and providers nationwide, and held roles at Proteus Digital Health and the RAND Corporation. He earned a BA in neurobiology from Harvard and an MPhil from Queens’ College, Cambridge.
Sessions
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}